ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three ...

Across the country, a small group of lawyers and care navigators help patients, often desperately ill, battle with health ...

Received an FDA Approvable Letter indicating the FDA will approve the Company’s PMA application for its Genio® system subject ...

PyroGenesis Inc. (“PyroGenesis”) ( (TSX:PYR) (OTCQX:PYRGF) (FRA:8PY1), a high-tech company that designs, develops, manufactures and commercializes all-electric plasma processes and sustainable solutio ...

Scott Mollen discusses “JY Citizen L.P. v. 333 E. 150 Street Realty” and “NNH Markets Corp. v. 31-18 24th Avenue.” ...

CNW/ - Paramount Resources Ltd. ("Paramount" or the "Company") (TSX: POU) is pleased to announce its first quarter 2025 ...

A measure now on the floor of the Nebraska Legislature would address some practices by intermediaries called pharmacy benefit managers that pharmacists say are harming their businesses.

HIGHLIGHTS Revenue for the first quarter of 2025 was $436.5 million, a one percent increase from the first quarter of 2024 ...

He built his fortune slowly over the course of a few decades through a career in insurance ... with a client list that now ...

Good afternoon, and welcome to Poste Italiane's First Quarter 2025 Results Conference Call. In a few moments, the CEO, Matteo Del Fante will take you through some opening remarks, and then, the CFO, ...

Results ...

JOET positions itself as a fund that combines quality and momentum investment strategies. Read why I take a neutral stance on ...